Work

Biomarkers, imaging and safety in resmetirom 52 week non-cirrhotic NASH phase 3 clinical trial, completed open-label arm of maestro-NAFLD-1

Year: 2022

Type: article

Source: Digestive and Liver Disease

DOI: 10.1016/j.dld.2022.01.094

Authors: Dr. S.A. Harrison, Dr. A. Mangia, Dr. P. Lasierra-Resa, Ms. S. Cubberley, Dr. R.A. Taub, Dr. G.W. Neff, Dr. Naim Alkhouri, Dr. Mustafa Bashir

Institutions: University of Oxford, Casa Sollievo della Sofferenza, Madrigal Pharmaceuticals (United States), Duke University, Arizona Liver Health, Covenant Research and Clinics (United States)

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4220852275

FWCI: 0.181

Cites:

Cited by: 1

Related to: 10